Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Queensland Health
Dow
Citi
Moodys
Novartis
Express Scripts
QuintilesIMS
Merck
Federal Trade Commission

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 019558

« Back to Dashboard

NDA 019558 describes PRINIVIL, which is a drug marketed by Merck and is included in one NDA. It is available from one supplier. Additional details are available on the PRINIVIL profile page.

The generic ingredient in PRINIVIL is lisinopril. There are twenty-one drug master file entries for this compound. Eighty-three suppliers are listed for this compound. Additional details are available on the lisinopril profile page.
Summary for 019558
Tradename:PRINIVIL
Applicant:Merck
Ingredient:lisinopril
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 019558
Medical Subject Heading (MeSH) Categories for 019558
Suppliers and Packaging for NDA: 019558
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PRINIVIL lisinopril TABLET;ORAL 019558 NDA Merck Sharp & Dohme Corp. 0006-0019 0006-0019-54 90 TABLET in 1 BOTTLE (0006-0019-54)
PRINIVIL lisinopril TABLET;ORAL 019558 NDA Merck Sharp & Dohme Corp. 0006-0106 0006-0106-54 90 TABLET in 1 BOTTLE (0006-0106-54)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength5MG
Approval Date:Dec 29, 1987TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength10MG
Approval Date:Dec 29, 1987TE:ABRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength20MG
Approval Date:Dec 29, 1987TE:ABRLD:No

Expired US Patents for NDA 019558

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck PRINIVIL lisinopril TABLET;ORAL 019558-006 Jan 28, 1994 ➤ Subscribe ➤ Subscribe
Merck PRINIVIL lisinopril TABLET;ORAL 019558-001 Dec 29, 1987 ➤ Subscribe ➤ Subscribe
Merck PRINIVIL lisinopril TABLET;ORAL 019558-002 Dec 29, 1987 ➤ Subscribe ➤ Subscribe
Merck PRINIVIL lisinopril TABLET;ORAL 019558-004 Oct 25, 1988 ➤ Subscribe ➤ Subscribe
Merck PRINIVIL lisinopril TABLET;ORAL 019558-003 Dec 29, 1987 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Daiichi Sankyo
McKesson
QuintilesIMS
Cipla
Harvard Business School
Accenture
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot